Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

ABSTRACT: This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China. About 268 eligible metastatic colorectal cancer patients after second-line therapy will be assigned to receive either regorafenib or fruquintinib, based on decision of the gastrointestinal physician according the patients’ condition.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2342564 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR